

WHAT IS CLAIMED IS:

1. A monoclonal antibody which specifically recognizes A β 11-x peptides.
- 5 2. A monoclonal antibody according to claim 1 which specifically recognizes the first 5 to 7 human amino acids of the β -secretase₁₁ cleavage site, *i.e.* Seq Id No.:1 and Seq Id No.:2 or the first 5 to 7 mouse amino acids of the β -secretase₁₁ cleavage site, *i.e.* Seq Id No.:3 and Seq Id No.:4, as immunogens.
- 10 3. An antibody as claimed in claims 1 or 2 that is detectably labeled.
4. An antibody as claimed in claim 3 wherein the detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.
- 15 5. An antibody as claimed in any one of claims 1 to 4 that is immobilized on a carrier.
6. A monoclonal antibody according to any one of claims 1 to 5, expressed by the hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the
20 Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.
7. The hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with
25 accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.
8. An immunoassay method for the determination or detection of A β 11-x peptides in a sample, the method comprising contacting the sample with an antibody to A β 11-x peptides as claimed in any one of claims 1 to 3 and determining
30 whether an immune complex is formed between the antibody and the A β 11-x peptide.

9. A method for the detection of the presence of A β 11-x peptides in a tissue sample, the method comprising:

obtaining a tissue sample from the body of a subject;

- 5 contacting the tissue sample with an imaging effective amount of a detectably labeled antibody as claimed in claims 3 or 4; and

detecting the label to establish the presence of A β 11-x peptides in the tissue sample.

- 10 10. A method according to claim 9 wherein the antibody that is detectably labeled, is expressed by at least one of the hybridoma cells as claimed in claim 7.

11. A method for the detection of the presence of A β 11-x peptides in a body fluid sample, the method comprising:

15 obtaining a body fluid sample from the body of a subject;

contacting the body fluid sample with an imaging effective amount of a detectably labeled antibody as claimed in claim 3 or 4; and

detecting the label to establish the presence of A β 11-x peptides in the body fluid sample.

20

12. A method according to claim 10 wherein the antibody that is detectably labeled, is expressed by at least one of the hybridoma cells as claimed in claim 7.

13. The use of a monoclonal antibody as claimed in any one of claims 1 to 6 in a method according to claims 9 or 10.

25

14. The use of an antibody as claimed in any of claims 1 to 6 for the diagnosis of β -amyloid-related diseases.

15. A diagnostic composition comprising an antibody as claimed in any of claims 1 to 6 and a pharmaceutically acceptable carrier.
- 5 16. An immunoassay kit for the diagnosis of β -amyloid-related diseases comprising an antibody as claimed in any of claims 2 to 5 and carrier means for the antibody.